[A22-96] Abemaciclib (breast cancer; adjuvant treatment) - Addendum to Commission A22-51
Last updated 20.10.2022
Project no.:
A22-96
Commission:
Commission awarded on 06.09.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
Adjuvant treatment of patients with HR-positive, HER2-negative, node-positive early-stage breast cancer at high risk of recurrence
Result of dossier assessment:
Unchanged after addendum:
- Premenopausal women: hint of minor added benefit
- Postmenopausal women: added benefit not proven
- Men: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A22-51 | Abemaciclib (breast cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-10-20 A G-BA decision was published.